Privia Health Group, Inc. PRVA R2KR3KPHARMA
Company Overview
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
Why Investors Should Care
Net profit has compounded at 18.6% per year over the last five years.
Revenue has grown at a 18.0% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.12B (+22.3% YoY); net profit $22.92M.
- Trailing 12 Months Year-on-year growth — revenue +21.4%, earnings +250.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.0%, profit CAGR 18.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 18.00% |
| 1 Year: | 21.40% |
Compounded Profit Growth
| 5 Years: | 18.58% |
| 1 Year: | 250.00% |
Stock Price Performance
| 1 Year: | -1.71% |
| 6 Months: | -11.22% |
| 3 Months: | -4.48% |
| 1 Month: | -6.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.32 · Oversold
P/E of 93.91 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 18.0% over 5 years.
- Profit CAGR of 18.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 93.9.
- Trading 26.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRVA Privia Health Group, Inc. R2KR3KPHARMA | 20.66 | 93.91 | $2.64B | 0.00% | 4.27% | 4.31% | 18.00% | 18.58% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 212.94M | 183.26M | 207.17M | 213.61M | 225.76M | 251.52M | 313.80M | 335.54M | 342.90M | 386.28M | 413.35M | 417.28M | 415.24M | 422.33M | 437.92M | 480.10M | 521.15M | 580.42M | 603.85M | 632.63M |
| Operating Income | 6.50M | 6.18M | 8.54M | 7.91M | -193.19M | -12.81M | -11.55M | -5.25M | -4.57M | 6.71M | 6.98M | 5.54M | 823.00K | 5.10M | 5.81M | 5.22M | 3.34M | 14.40M | 7.42M | 11.77M |
| Net Income | 5.41M | 5.28M | 16.68M | 5.40M | -172.53M | -9.12M | -17.51M | -10.47M | 1.62M | 7.32M | 7.27M | 5.64M | 2.98M | 3.47M | 3.54M | 4.22M | 2.69M | 6.86M | 3.06M | 9.05M |
| Diluted EPS | 0.06 | 0.06 | 0.17 | 0.06 | -1.68 | -0.09 | -0.16 | -0.10 | 0.01 | 0.06 | 0.06 | 0.05 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.05 | 0.02 | 0.07 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 786.36M | 817.08M | 966.22M | 1.36B | 1.66B | 1.74B | 2.12B |
| Operating Income | 16.06M | 25.38M | -217.44M | -19.12M | 20.65M | 16.98M | 34.23M |
| Net Income | 8.24M | 31.24M | -188.23M | -8.59M | 23.08M | 14.38M | 22.92M |
| Diluted EPS | 0.09 | 0.33 | -1.83 | -0.08 | 0.19 | 0.11 | 0.18 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 328.97M | 686.37M | 792.81M | 999.90M | 1.14B | 1.37B |
| Total Equity | 86.04M | 107.46M | 146.75M | 426.87M | 499.09M | 561.44M | 635.18M | 737.22M |
| Cash & Equivalents | - | - | 84.63M | 320.58M | 347.99M | 389.51M | 491.15M | 479.69M |
| Total Liabilities | - | - | 185.32M | 236.19M | 273.76M | 392.51M | 452.34M | 578.43M |
| Current Liabilities | - | - | 146.94M | 190.46M | 264.27M | 386.95M | 449.15M | 568.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 24.36M | 38.89M | 55.06M | 47.20M | 80.78M | 109.28M | 163.40M |
| Investing Cash Flow | -5.71M | -380.00K | -32.77M | -104.00K | -42.97M | -11.98M | -181.57M |
| Financing Cash Flow | -10.87M | -767.00K | 213.66M | -19.68M | 3.71M | 4.33M | 6.70M |
| Capital Expenditure | -5.71M | -380.00K | -547.00K | -104.00K | -113.00K | - | - |
| Free Cash Flow | 18.65M | 38.51M | 54.51M | 47.09M | 80.67M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | 2.0% | 3.1% | -22.5% | -1.4% | 1.2% | 1.0% | 1.6% |
| Net Margin % | 1.0% | 3.8% | -19.5% | -0.6% | 1.4% | 0.8% | 1.1% |
| ROE % | 7.7% | 21.3% | -44.1% | -1.7% | 4.1% | 2.3% | 3.1% |
| ROCE % | - | 13.9% | -43.8% | -3.6% | 3.4% | 2.5% | 4.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.76% | 21.40M | $444.96M |
| 2 | FMR, LLC | 10.06% | 12.85M | $267.12M |
| 3 | Durable Capital Partners Lp | 9.11% | 11.64M | $241.91M |
| 4 | Vanguard Portfolio Management LLC | 5.15% | 6.57M | $136.64M |
| 5 | Rubicon Founders LLC | 4.67% | 5.97M | $124.14M |
| 6 | Vanguard Capital Management LLC | 4.04% | 5.16M | $107.21M |
| 7 | State Street Corporation | 3.84% | 4.91M | $101.99M |
| 8 | Van Berkom & Associates Inc. | 2.91% | 3.71M | $77.16M |
| 9 | Geode Capital Management, LLC | 2.45% | 3.13M | $65.08M |
| 10 | Riverbridge Partners LLC | 2.35% | 3.00M | $62.34M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRVA
3 Reasons to Avoid PRVA and 1 Stock to Buy Instead - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQY1VVUkRqS0Z2Y3NwV3N6dWxabmRJTG9NQ2ZPZThPT0tFSTd0VmZybl9wY2pHTlY0X1RfdkNrdVZ0dURwMDBZSS1TZjdoTXN2T2xfYzNNVE5JaUZXUXRaSU9MR2dPcEVVVHY5bGZzWFRzeThvTXdHZTdVUFlGczRVMUNJcFBpMENRZkY3Q2…
Privia Health (NASDAQ:PRVA) Surprises With Q2 CY2026 Sales - StockStory
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPc3g3QTVDOFFoWTRyR1VkVjdFN1owNXlrbEgxQzVDd2tPUXVXbTZmM21pUFBTMzBBck5ja2NGWGszTFpybW5hTDdHNDc3YUZPZWZfQTZGYWRTZjJNRi1JS21rZVBGZG1mQTBlMHF4Nm1xbHNEcHBtSktJNjN1RjV2STl5al9DNzA5TWplRm…
A 20-year healthcare executive is set to join Privia Health's board - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQSV85QkhNaThNZHY4OVJ5dHh0VmhHNEdDRTh1QmVwTmFDZVl2X3E0SDY1MEVmNkpKWTJhRXltQVpub2dmM2JXYTYxT2xna1pZY1A1cEdiVGVLdnNmLWJYNWh0RDJ1emxreFo2UURySFJGRlpMVzlFc3R6M3NpcmpYQ1l1a1laQzM4ZXpwME…
(PRVA) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTng3b01jc3VjV0xsR3NJWTZjQzVFZ0s1Y2ZLMk5udFE5ZEx6allOeFB2Z0RTVkc5cjFJOTRQUG5TY0FqbHY0SUNCenVrVGkyTXdJZU56bXFNdEVfbzVVMXA1MmZnWHlsVU9ZeTBtWDF3YnU1UTRpS2FBX042aG9zT3hQU05FdmMxSWJkWD…
1 Cash-Producing Stock for Long-Term Investors and 2 Facing Challenges - FinancialContent
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxObHkyQ1dmekRXcmRwdXEyLVZPY2RvZDR5OG44cUh1S28yOHFPckMwRS13UWt3eFB6bGlTZ0JRc2RlcVNJR0UzelZZTmFwdmNoSmJoSEZiZjk1eklYTWlrX0tFTDZaSHVhYlVkVFRRZHB2ZW9Oa21yWlBWVTlIVnN3bUtiSmZPUFAxOU1FU2…
Is Privia Health Group (PRVA) A Bargain As Earnings Growth And Guidance Improve? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPZVhxUGlKWmE0TW5ZbkZzdjZnVm1ENFRsb2RLU085eVpxR09ES0hfbGx4QTI2YXBXMk52RUxqTGVoSkdPTEJpSXk4ZExKUGJDZElEU09CY3dyTk1sR1A2cXlmczAzd1c3QjNuak1OY1YtOWZCRzMzM1NlNjc1dXp5NFN3c3BvWnpvc2ZZTm…
PRVA — Frequently Asked Questions
What is the current share price of Privia Health Group, Inc. (PRVA)?
As of 2026-09-07 16:24 PDT, Privia Health Group, Inc. (PRVA) trades at $20.66 on NasdaqGS. Its 52-week range is $20.02 to $28.10.
What is the market capitalisation of PRVA?
Privia Health Group, Inc. (PRVA) has a market capitalisation of $2.64B on NasdaqGS.
What is the P/E ratio of PRVA?
PRVA trades at a trailing price-to-earnings (P/E) ratio of 93.91. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.62.
What is the return on equity (ROE) of PRVA?
PRVA has a return on equity (ROE) of 4.31%. Its return on capital employed (ROCE) is 4.27%.
Is PRVA a good stock to buy?
This page provides a data-driven analysis of Privia Health Group, Inc. (PRVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.